Your Account
Immunotherapeutic Approaches
(To see other currencies, click on price)
Add to basket  


Main description:

Treatment of glioma is currently one of the most challenging problems in oncology, as well as in neurosurgery. Despite major advances in our understanding of the pathomechanism, diagnosis by imaging and the availability of powerful therapeutic tools, the life expectancy of patients with glioblastoma has only been slightly prolonged and a cure remains elusive. None of the currently available surgical tools, including operative microscopes, lasers and image-guided surgery, can enable the detection and removal of all of the tumor tissue. In recent years, however, the landscape has been changing immeasurably, and molecular studies over the past two decades have identified a variety of genetic aberrations that are specifically associated with individual types of gliomas. In addition, certain molecular abnormalities have been linked to therapy responses, thereby establishing clinical biomarkers and molecular targets, and the use of novel agents is being investigated. These agents have been specifically engineered to exert specific cytotoxicity against gliomas, either on their own as single agents or in combination with other modalities. Moreover, there has been an enormous surge of interest in the area of immunology and immunotherapy, which has been facilitated by our understanding of the molecular basis of gliomas. Although several kinds of immunotherapeutic trials have been undertaken, we still await a great breakthrough in terms of clinical efficacy to prolong the survival time of glioma patients.


Discusses in depth the potential of innovative methods in the broad field of glioma immunology and immunotherapy

Useful for clinicians, clinical scientists and basic scientists

Reviews the basic and clinical background, and proceeds from basic science at the bench to the bedside to give a realistic evaluation of the immunology and immunotherapy of glioma

Written by internationally distinguished experts working in basic science and clinical neurooncology

Back cover:



Molecular Biology of Glioma.- Recent Surgical Management of Gliomas.- Recent Medical Management of Glioblastoma.- Basic Concepts in Glioma Immunology.- Mechanisms of Immune Evasion by Gliomas.- Glioma Antigen.- Cytokine Therapy.- Immunotherapeutic Approach with Oligodeoxynucleotides Containing CpG Motifs (CpG‑ODN) in Malignant Glioma.- Adoptive Cell Transfer Therapy for Malignant Gliomas.- Monoclonal Antibody Therapy for Malignant Glioma.- Animal Models for Vaccine Therapy.- Immunogene Therapy.- Peptide Vaccine.- Active Immunotherapy: Oncolytic Virus Therapy Using HSV‑ 1.- Dendritic Cell Vaccines.- Antigen‑Receptor Gene‑Modified T Cells for Treatment of Glioma.- Glioma Stem Cell Research for the Development of Immunotherapy.


ISBN-13: 9781461431466
Publisher: Springer (Springer New York)
Publication date: April, 2012
Pages: 246

Subcategories: General Issues, Immunology, Oncology


RYUYA YAMANAKA is now a Professor at Kyoto Prefectural University of Medicine, Kyoto, Japan. He earned his MD at Niigata University, Japan, in 1982 and completed a neurosurgical residency training at its affiliated hospitals. He received his academic degree (Dr Med Sci) from Niigata University. Following research fellowships at the National Institutes of Health in the United States from 1994 to 1998, he assumed the position of Assistant Professor and Lecturer at the Department of Neurosurgery in the Brain Research Institute at Niigata University. In 2006, he was promoted to Professor of the Research Center of Innovative Cancer Therapy at Kurume University School of Medicine. He joined the faculty at Kyoto Prefectural University of Medicine in 2010. His main research interests include translational biochemical research in clinical oncology, including brain tumors. He is a member of international and national scientific organizations, including the American Association for Cancer Research (AACR ), American Society of Clinical Oncology (ASCO), Japanese Cancer Association (JCA), Japanese Society of Medical Oncology (JSMO) and Japan Neurosurgical Society (JNS). He has board certifications for Medical Oncology, Neurosurgery, Stroke and Cerebrovascular Diseases.